US LNG exports surge but will buyers in China turn up?
Myriam Curet, Executive Vice President and Chief Medical (TASE:BLWV) Officer at Intuitive Surgical Inc . (NASDAQ:ISRG), a $202 billion medical technology giant, recently sold a significant portion of the company’s stock. According to a Form 4 filing with the Securities and Exchange Commission, Curet sold 3,031 shares on March 3, 2025, at a weighted average price of $577.30, totaling approximately $1.75 million. InvestingPro data shows the company trades at a premium valuation with a P/E ratio of 87x.
This sale was conducted under a trading plan that complies with SEC Rule 10b5-1. Following this transaction, Curet’s direct ownership in the company stands at 353 shares.
In addition to the sale, the filing detailed other transactions, including the withholding of shares to cover tax obligations related to the settlement of performance stock units. These transactions, dated February 28, 2025, involved 497 and 2,486 shares at a price of $563.77 each, amounting to approximately $280,193 and $1.40 million, respectively.
The transactions reflect ongoing activity in Curet’s holdings, which are part of her compensation package as a senior executive at Intuitive Surgical.
In other recent news, Intuitive Surgical reported strong fourth-quarter 2024 results, surpassing expectations with a 10% and 24% beat on revenue and earnings per share (EPS), respectively. The company projected a 13-16% year-over-year increase in procedure volume for 2025, aligning with its historical trend of setting conservative initial targets. Analysts from Piper Sandler raised their price target for Intuitive Surgical to $670, citing the company’s robust earnings and revenue performance. RBC Capital Markets maintained an Outperform rating with a price target of $641, emphasizing the anticipated launch of the da Vinci (EPA:SGEF) 5 (dV5) system as a key growth driver.
Oppenheimer kept a Perform rating on Intuitive Surgical, noting the company’s GAAP EPS of $1.88, which exceeded both their and the consensus estimates. Despite positive developments, Oppenheimer expressed concerns about market saturation and valuation metrics. Bernstein analysts maintained an Outperform rating with a $700 price target, highlighting a 38% year-over-year increase in EPS and strong margin performance. They anticipate consistent financial improvement and transformational product cycles driving growth.
Truist Securities increased their price target to $666, maintaining a Buy rating and highlighting the potential for significant upside due to conservative guidance. The upcoming full launch of the dV5 system is expected to be a focal point for the company’s strategy. Overall, Intuitive Surgical’s recent performance and strategic plans have garnered positive attention from several analyst firms, reflecting optimism about its future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.